SAN DIEGO--(BUSINESS WIRE)--Wall Street Beats is pleased to announce an investor conference call with Doug Ingram, CEO of Sarepta Therapeutics, following the landmark FDA approval expanding the label for ELEVIDYS (delandistrogene moxeparvovec-rokl) to treat Duchenne muscular dystrophy (DMD) patients aged four and above. The call will be hosted by David Maris, a six-time #1 ranked pharma analyst and partner at Wall Street Beats.
Maris stated, "Sarepta's expanded label approval for ELEVIDYS is a landmark achievement that underscores Sarepta's relentless pursuit of solutions for the Duchenne community and the transformative potential of gene therapy. This is an exciting opportunity to host Sarepta's CEO, Doug Ingram, and hear more about Sarepta's long-term strategic vision and the significant milestone this approval represents."
Key Points:
- Ground-Breaking Advance for Patients: The expanded label includes both ambulatory and non-ambulatory DMD patients, representing a significant milestone in gene therapy and patient care.
- Strategic Insights: This call aims to delve deeper into Sarepta's longer-term goals and strategic initiatives.
- Landmark Approval: This approval marks a watershed moment for the Duchenne community and the promise of gene therapy.
Event Details:
- Date: June 21, 2024
- Time: 2:00 p.m. ET/11:00 a.m. PT
- Webcast: https://wallstreetbeats.com/interview
Join us to gain deeper understanding and insights directly from Sarepta's leadership on this pivotal development.
Users can sign up for a 24-hour preview to access the interview.
